Metabolic · ~3 min read
Cagrilintide: What It Is, How It Works & What the Research Shows
Overview
Cagrilintide is a long-acting analog of amylin, a hormone released alongside insulin that promotes fullness and slows stomach emptying. It acts on a different appetite pathway than GLP-1 drugs, which is why it is studied in combination with semaglutide (CagriSema). On its own, 4.5 mg weekly produced about 10.8% weight loss at 26 weeks in a phase 2 Lancet trial. Combined with semaglutide in the REDEFINE 1 trial, it produced about 20.4% weight loss at 68 weeks.
Why researchers study it
Appetite & fullness
Mimics amylin to increase satiety and slow stomach emptying.
Pairing with semaglutide
Studied as CagriSema, which reached about 20% weight loss.
Weight management
About 10.8% weight loss on its own in a phase 2 trial.
How it works
A long-acting amylin analog studied for signaling involved in satiety and food intake. Its monotherapy findings are distinct from combination-treatment findings.
Adamantane & the blood–brain barrier
Chemically attaching an adamantane group to a peptide can increase its lipid (fat) solubility. Researchers hypothesize that this modification may help certain compounds cross the tightly regulated blood–brain barrier. The effect depends on the specific modified molecule; greater lipid solubility alone does not establish brain delivery or clinical benefit. This does not apply automatically to the unmodified peptide and is not a reconstitution additive.
What the research shows
- A randomized phase 2 trial assessed body-weight reduction in adults with overweight or obesity without diabetes.
- Long-acting amylin receptor activity is a metabolic research target; combination studies must be evaluated separately.
Typical protocol
Reconstitute a 10 mg vial with 1 mL bacteriostatic water for 10 mg/mL. Typical range: 0.25–4.5 mg 1x daily · 1–2x weekly (split dose), As long as needed.
Common stacks
- Cagrilintide + Semaglutide — A randomized phase 1b study investigated concomitant administration for weight management.
- Cagrilintide + Tirzepatide — Pairs amylin activity with a dual GIP/GLP-1 agonist for complementary appetite control.
Potential benefits & side effects
Potential benefits
- Significant reduction in appetite and food noise
- Clinically meaningful weight loss
- Improved blood sugar and insulin sensitivity
- Improvements in blood pressure, lipids and liver fat
Side effects
- Nausea, vomiting, diarrhea or constipation (most common, usually during dose increases)
- Reduced appetite to the point of under-eating
- Fatigue and occasional headache
- Increased heart rate (especially triple/glucagon agonists)
- Rare: gallbladder problems or pancreatitis — seek care for severe abdominal pain
Lifestyle factors
- Protein: aim for adequate protein (about 0.7–1 g per lb of goal body weight) to preserve muscle during weight loss.
- Resistance training: lift 2–4x per week to protect lean mass.
- Hydration & fiber: drink plenty of water and eat fiber to reduce constipation and nausea.
- Meal size: eat smaller meals and stop at fullness; greasy, heavy meals worsen GI side effects.
- Titrate slowly: stay at a dose until side effects settle before increasing.